March 13, 2008 - Kingfisher Healthcare received the CE mark for its KFH Novo medical device, which utilizes Bio-Electric Stimulation Therapy (BEST) to assist in and improve upon the healing of chronic wounds including venous leg ulcers, diabetic ulcers and pressure sores.
KFH Novo is the latest addition to Kingfisher's line of noninvasive energy therapies, said the company.
This form of electrotherapy reportedly enhances the physiological processes of wound healing at a cellular level, increasing protein synthesis levels, stimulating angiogenesis and fibroblasts and increasing levels of ATP production to restart and regenerate tissue healing.
Designed for home use, KFH Novo is portable, and reportedly features a patented touch-screen panel. KFH Novo is expected to enter the U.S. market in 2009.
For more information: www.kfhealth.com